LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
UTRECHT, The Netherlands and PHILADELPHIA, May 06, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, "LAVA," or "Company"), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody platform of bispecific gamma-delta (δ2) T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat at the Citizens JMP Life Sciences Conference.
荷兰乌得勒支和费城，2024年5月6日（GLOBE NEWSWIRE）——专注于开发其专有的双特异伽玛-三角洲（2）T细胞参与剂Gammabody平台的临床阶段免疫肿瘤学公司LAVA Therapeutics N.V.（纳斯达克股票代码：LVAX，“LAVA” 或 “公司”）今天宣布，LAVA Therapeutics总裁兼首席执行官斯蒂芬·赫利将参与在 Citizens JMP 生命科学大会的炉边谈话中。
Presentation Details
Format: Fireside Chat
Date: Monday, May 13, 2024
Time: 10:00 a.m. ET
演示详情
格式：炉边聊天
日期：2024 年 5 月 13 日星期一
时间：美国东部时间上午 10:00
A webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at The replay will be archived for 90 days following the presentation date.
可以在LAVA Therapeutics网站投资者关系部分的 “活动” 选项卡下观看炉边谈话的网络直播。重播将在演示日期后的90天内存档。